Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Puma Biotechnology (PBYI) Sell-Off on ASCO Abstract 'May be Overdone', Stifel Says
May 14, 2015 6:26 AM EDTStifel analyst Thomas Shrader weighed in on Puma Biotechnology (NYSE: PBYI) after the 20% sell-off in the stock following the ASCO abstract. He said the reaction in the stock may be overdone.
"An unexpectedly strong showing by the control arm in Pumas ExteNet trial left neratinib little room to improve on SOC," Shrader commented. "Its still a positive trial to our eyes, but the risk benefit for... More
Puma Biotech (PBYI) Reports Publication of Abstracts for ASCO
May 13, 2015 5:16 PM EDTPuma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the release of four abstracts on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be... More
